# Biomarkers

DRAGEN biomarker support is tabulated below. Please refer to the respective sections for details on requirements and how to configure each module.

|                                                                                                                                                     | WES T/N                         | WES T/O                    | WGS T/N                  | WGS T/O   |
| --------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------- | -------------------------- | ------------------------ | --------- |
| [HRD](https://help.dragen.illumina.com/product-guides/dragen-v4.5/dragen-dna-pipeline/biomarkers/biomarker-hrd)                                     | Supported                       | Supported                  | Supported                | Supported |
| [MSI](https://help.dragen.illumina.com/product-guides/dragen-v4.5/dragen-dna-pipeline/biomarkers/biomarker-msi)                                     | Supported                       | Supported                  | Supported                | Supported |
| [TMB](https://help.dragen.illumina.com/product-guides/dragen-v4.5/dragen-dna-pipeline/biomarkers/biomarker-tmb)                                     | Supported                       | Supported                  | Supported                | Supported |
| [Fragmentomics](https://help.dragen.illumina.com/product-guides/dragen-v4.5/dragen-dna-pipeline/biomarkers/biomarker-fragmentomics)                 | Unsupported                     | Supported                  | Unsupported              | Supported |
| [Mutational Signatures](https://help.dragen.illumina.com/product-guides/dragen-v4.5/dragen-dna-pipeline/biomarkers/biomarker-mutational-signatures) | Unsupported<sup>\[1],\[2]</sup> | Unsupported<sup>\[2]</sup> | Supported<sup>\[1]</sup> | Supported |

***

<sup>\[1]</sup> All Tumor/Normal workflows automatically perform mutational signatures analysis with no additional options required.

<sup>\[2]</sup> WES sequences \~1% of the genome compared to WGS, resulting in \~1% of the somatic mutations available for analysis. While analysis execution is possible, it is not recommended; results are likely not reliable with such limited input.